A Bioavailability Study of ODM-201 Formulations With a Safety and Tolerability Extension Component in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer

Trial Profile

A Bioavailability Study of ODM-201 Formulations With a Safety and Tolerability Extension Component in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Darolutamide (Primary)
  • Indications Prostate cancer
  • Focus Pharmacokinetics
  • Acronyms ARAFOR
  • Sponsors Orion; Orion Pharma
  • Most Recent Events

    • 22 Sep 2016 Planned End Date changed from 1 Jul 2016 to 1 Jul 2017.
    • 10 May 2016 Results of combined long-term safety and efficacy data from three studies including this study presented at the 111th Annual Meeting of the American Urological Association
    • 13 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Jul 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top